Aktis Oncology AKTS
$16.15 −$0.25 (-1.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.46 +1.92%
Open$16.32
Prev close$16.40
Day range$16.00 – $16.74
Volume375.0K
Market cap$901.14M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$3.91M+147.3% YoY
Operating profit-$34.75M-90.9% YoY
Net profit-$29.94M-92.7% YoY
Diluted EPS-$0.54-82.6% YoY
Free cash flow-$26.82M-55.7% YoY
Operating cash flow-$26.05M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-837.5%
Net margin-706.8%
Return on equity-53.6%
Return on assets-21.6%
Return on invested capital-59.4%
Current ratio14.22
Liabilities / assets13.8%
Cash & investments$492.93M
Total debt$9.38M
Net cash (debt)$483.55M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $3.91M | $3.38M | $3.23M | $6.50M | $1.87M |
| Total Operating Revenue | $3.91M | $3.38M | $3.23M | $6.50M | $1.87M |
| Operating Expense | $38.65M | $32.28M | $25.93M | $81.18M | $19.25M |
| Selling and Admin Expenses | $5.88M | $6.40M | $5.34M | $12.60M | $2.51M |
| -General & Admin Expense | $5.88M | $6.40M | $5.34M | $12.60M | $2.51M |
| Research & Development | $32.13M | $25.28M | $20.04M | $67.45M | $16.49M |
| Depreciation & Amortization & Depletion | $647,000.00 | $599,000.00 | $556,000.00 | $1.13M | $242,000.00 |
| -Depreciation & Amortization | $647,000.00 | $599,000.00 | $556,000.00 | $1.13M | $242,000.00 |
| Operating Profit | -$34.75M | -$28.90M | -$22.71M | -$74.68M | -$17.38M |
| Net Non-Operating Interest Income (Expense) | $4.82M | $4.77M | $4.38M | $11.01M | $2.25M |
| Non-Operating Interest Income | $4.82M | $4.77M | $4.38M | $11.01M | $2.25M |
| Other Income (Expense) | -$14,000.00 | -$10,000.00 | -$3,000.00 | -$56,000.00 | -$11,000.00 |
| Other Non-Operating Income (Expenses) | -$14,000.00 | -$10,000.00 | -$3,000.00 | -$56,000.00 | -$11,000.00 |
| Pretax Profit | -$29.94M | -$24.14M | -$18.33M | -$63.73M | -$15.14M |
| Net Profit | -$29.94M | -$24.14M | -$18.33M | -$63.73M | -$15.14M |
| Profit from Continuing Operations | -$29.94M | -$24.14M | -$18.33M | -$63.73M | -$15.14M |
| Net Income to Parent Company | -$29.94M | -$24.14M | -$18.33M | -$63.73M | -$15.14M |
| Net Income to Common Stockholders | -$29.94M | -$24.14M | -$18.33M | -$63.73M | -$15.14M |
| Basic EPS | -$0.54 | -$0.44 | -$0.38 | -$1.21 | -$0.29 |
| Diluted EPS | -$0.54 | -$0.44 | -$0.38 | -$1.21 | -$0.29 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $532.48M | $557.60M | $576.80M | $264.89M | $264.89M |
| Total Current Assets | $499.89M | $524.54M | $543.94M | $230.31M | $230.31M |
| Cash and Cash Equivalents & Short-Term Investments | $492.93M | $517.32M | $538.48M | $226.79M | $226.79M |
| -Cash and Cash Equivalents | $68.32M | $82.49M | $371.63M | $37.78M | $37.78M |
| -Short Term Investments | $424.61M | $434.83M | $166.85M | $189.00M | $189.00M |
| Other Current Assets | $6.96M | $7.22M | $5.46M | $3.52M | $3.52M |
| Total Non-Current Assets | $32.60M | $33.06M | $32.86M | $34.58M | $34.58M |
| Net PPE | $27.11M | $28.20M | $28.11M | $27.25M | $27.25M |
| -Gross PPE | $35.12M | $35.27M | $34.31M | $32.79M | $32.79M |
| -Accumulated Depreciation | -$8.02M | -$7.08M | -$6.20M | -$5.55M | -$5.55M |
| Other Non-Current Assets | $5.49M | $4.86M | $4.75M | $7.33M | $7.33M |
| Total Liabilities | $73.61M | $72.76M | $70.69M | $411.03M | $411.03M |
| Total Current Liabilities | $35.16M | $32.13M | $27.91M | $31.24M | $31.24M |
| Payables | $1.44M | $2.53M | $1.23M | $1.74M | $1.74M |
| -Accounts Payable | $1.44M | $2.53M | $1.23M | $1.74M | $1.74M |
| Current Accrued Expenses | $12.52M | $8.19M | $5.05M | $4.96M | $4.96M |
| Short-Term Debt and Capital Lease Obligation | $1.46M | $1.48M | $1.43M | $1.32M | $1.32M |
| -Current Capital Lease Obligation | $1.46M | $1.48M | $1.43M | $1.32M | $1.32M |
| Current Deferred Liabilities | $15.23M | $17.34M | $18.96M | $18.66M | $18.66M |
| Total Non-Current Liabilities | $38.45M | $40.63M | $42.78M | $379.80M | $379.80M |
| Long Term Debt and Capital Lease Obligation | $9.38M | $9.76M | $10.15M | $10.23M | $10.23M |
| -Long Term Capital Lease Obligation | $9.38M | $9.76M | $10.15M | $10.23M | $10.23M |
| Non-Current Deferred Liabilities | $29.07M | $30.87M | $32.63M | $36.16M | $36.16M |
| Convertible preferred securities | $0.00 | $0.00 | $0.00 | $333.41M | $333.41M |
| Total Equity | $458.87M | $484.84M | $506.11M | -$146.15M | -$146.15M |
| Stockholders' Equity | $458.87M | $484.84M | $506.11M | -$146.15M | -$146.15M |
| Capital Stock | $5,000.00 | $5,000.00 | $5,000.00 | $0.00 | $0.00 |
| -Common Stock | $5,000.00 | $5,000.00 | $5,000.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $689.77M | $684.61M | $681.23M | $10.37M | $10.37M |
| Retained Earnings | -$228.97M | -$199.03M | -$174.89M | -$156.56M | -$156.56M |
| Gains/Losses Not Affecting Retained Earnings | -$1.93M | -$745,000.00 | -$241,000.00 | $42,000.00 | $42,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$26.05M | -$20.59M | -$24.24M | -$64.13M | -$15.24M |
| Net cash flow from continuing operations | -$26.05M | -$20.59M | -$24.24M | -$64.13M | -$15.24M |
| Net Income from Continuing Operations | -$29.94M | -$24.14M | -$18.33M | -$63.73M | -$15.14M |
| Depreciation & Depletion & Amortization | $942,000.00 | $879,000.00 | $652,000.00 | $2.33M | $695,000.00 |
| Change in Working Capital | $1.41M | $489,000.00 | -$9.06M | -$3.23M | -$1.19M |
| -Change in Receivables | -$278,000.00 | -$144,000.00 | -$1.11M | $1.03M | $804,000.00 |
| -Change in Prepaid Assets | $540,000.00 | -$1.62M | -$828,000.00 | -$872,000.00 | -$1.13M |
| -Change in Payables and Accrued Expense | $5.59M | $5.50M | -$1.89M | $2.16M | $903,000.00 |
| -Change in Other Current Assets | -$142,000.00 | $488,000.00 | -$1.69M | $1.35M | $417,000.00 |
| -Change in Other Current Liabilities | -$404,000.00 | -$350,000.00 | -$327,000.00 | -$1.40M | -$317,000.00 |
| -Change In Other Working Capital | -$3.91M | -$3.38M | -$3.23M | -$5.50M | -$1.87M |
| Net cash flow from investing | $10.17M | -$268.71M | $20.54M | $65.96M | -$126.46M |
| Net Cash Flow from Continuing Investing Activities | $10.17M | -$268.71M | $20.54M | $65.96M | -$126.46M |
| Net PPE Purchase and Sale | -$772,000.00 | -$1.26M | -$1.85M | -$9.58M | -$4.15M |
| Net Investment Purchase and Sale | $10.95M | -$267.45M | $22.40M | $75.55M | -$122.30M |
| Financing Cash Flow | $1.71M | $156,000.00 | $337.55M | -$1.21M | -$772,000.00 |
| Net Cash Flow from Continuing Financing Activities | $1.71M | $156,000.00 | $337.55M | -$1.21M | -$772,000.00 |
| Net Common Stock Issuance | $0.00 | $0.00 | $339.78M | – | – |
| Proceeds from Stock Option Exercised | $1.71M | $156,000.00 | $30,000.00 | $336,000.00 | $258,000.00 |
| Net Other Financing Charges | $0.00 | $0.00 | -$2.26M | -$1.55M | -$1.03M |
| Ending Cash Balance | $69.47M | $83.64M | $372.78M | $38.93M | $38.93M |
| Net Change in Cash | -$14.17M | -$289.14M | $333.85M | $625,000.00 | -$142.47M |
| Beginning Cash Balance | $83.64M | $372.78M | $38.93M | $38.31M | $181.40M |
| Free Cash Flow | -$26.82M | -$21.85M | -$26.10M | -$73.71M | -$19.40M |
| Net Preferred Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on AKTS.
Sign in to join the discussion.